Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Plixorafenib · FORE-8394, PLX-8394

Small molecule · Degrader of BRAF · developed by Fore Biotherapeutics

Early Phase 1 Most advanced trial

What is Plixorafenib?

Plixorafenib is an orally bioavailable BRAF inhibitor that acts as a dimer breaker, binding dimeric BRAF mutants, including BRAF fusions and splice variants, as well as BRAFV600 monomers. It is being studied in BRAF V600E-mutated tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FORE-8394, PLX-8394
Drug type
Small molecule
Targets
BRAF
Mechanism
Degrader of BRAF
Pathways
MAPK/ERK signaling
Therapy area
Oncology
Developer
Fore Biotherapeutics
In trials of
INCY
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1
UNII
J2L7Z273SG

Conditions studied

BRAF V600E Mutation

Other drugs acting on BRAF

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.